Tranzyme (TZYM -0.4%) says it's completed its chemistry-based drug discovery collaboration with...


Tranzyme (TZYM -0.4%) says it's completed its chemistry-based drug discovery collaboration with Bristol-Myers Squibb (BMY +0.1%). TZYM has transferred compounds from the joint research efforts to BMY for further development across multiple drug targets. As such, TZYM will retain the option to further pursue select collaboration targets for internal development.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs